Actusnews Wire - French company specializing in the dissemination of regulated information

  BASTIDE company press release from 20/03/2024

  20/03/2024 - 18:30

2023-2024 half-yearly results : Organic growth up 5.7%, EBITDA up 7.5%, Increase in recurring operating profit despite the inflationary context and margin of 8.3%. 2023-2024 outlook confirmed

Caissargues, March 20, 2024

In € millions - Year ended June 30 H1 2022-2023 H1 2023-2024 Change
Revenue 249.7 265.0 +6.1 %
EBITDA* 49.9 53.6 +7.5 %
EBITDA margin 20.0% 20.2%  
Recurring operating profit 21.5 21.9 +2.1%
Recurring operating margin 8.6% 8.3%  
Operating profit 18.9 20.7 +9.5%
Financial result -6.9 -11.9  
Taxes -3.7 -5.1  
Net profit from continuing operations 8.3 3.6 -56.6%
Net loss from discontinued operations -5.7 -1.2  
Net profit, Group share 2.6 2.4 -7.7%

* EBITDA: recurring operating income + net depreciation, amortization and provisions.

Groupe Bastide's 2023-2024 half-yearly consolidated financial statements have been reviewed by the Group's Statutory Auditors and were approved by its Board of Directors on March 18, 2024. The half-yearly results presentation will be available on the Group's website from 2:30 pm on March 21, 2024 in the "Investors" section. The half-yearly financial report will be available on the website before March 31, 2024, and will be the subject of a press release.

Revenue up 6.1%

Groupe Bastide's activity remained dynamic in first-half 2023-2024, posting growth of 6.1%, of which 5.7% in organic terms alone[1]. Revenue for the period amounted to €265.0 million.

The more technical business activities (Respiratory, Nutrition-Perfusion-Stomatherapy) maintained strong momentum and recorded revenue of €158.8 million, up 12.2% (up 10.5% on an organic basis). These strategic activities are driving the Group's growth, and now account for 60% of total revenue.

The “Homecare” business came in at €106.2 million, down 0.6% on an organic basis (down 1.6% on a reported basis). While sales continue to be impacted by the inflationary context, rental activities remain solid, posting revenue of €38.1 million, up 4.5% for the period.

International business accounted for almost 18% of revenue over the half-year.

Increase in recurring operating profit despite the inflationary context

Over the half-year, in an inflationary context, the shift in the product mix – following Groupe Bastide's strategic decision to develop its more technical business activities – led to a significant improvement in the Group's gross margin, which rose by 110 basis points to 67.2%.

EBITDA rose by 7.5% to €53.6 million, representing an increased margin of 20.2% (up 20 basis points), despite the negative 150 basis point impact of payroll costs, due both to wage inflation and significant growth in home healthcare services.

Recurring operating profit increased by 2.1% to €21.9 million, while recurring operating margin came in at 8.3%, in line with the Group's strategic roadmap.

Operating profit rose by 9.5% to €20.7 million. Non-recurring expenses, were halved compared with the first half of 2022-2023, and include various extraordinary expenses such as restructuring costs of €0.4 million.

Financial expenses came to €11.9 million (versus €6.9 million in first-half 2022-2023), of which €1.1m related to IFRS 16, due to the automatic impact of the increase in interest rates. The cost of average debt came to 6.2%.

Net profit from continuing operations stood at €3.6 million, after taking into account a €5.1 million tax expense.

Net loss from discontinued operations came in at €1.2 million for the half-year, due to the finalization of the Livramedom disposal.

Financial structure

Cash flow from operations came to €34.3 million, including an increase in working capital of around €10 million, largely due to non-recurring items, including the discontinuation of factoring in the community healthcare sector (€6 million) and a one-off delay in receivables (€2 million) which was resolved in January.

Net operating investments amounted to €25.7 million, or 9.7% of revenue, compared with 10.1% for first-half 2022-2023. This tight control over net operating investments is all the more remarkable in that it has been achieved against a backdrop of strong growth in the more capital-intensive rental business. Some 90% of these investments involve the purchase of medical devices for new capacity or existing capacities to renew, which are then leased to the customer.

Operating free cash flow (cash flow from operations after cash flows related to acquisitions of property, plant & equipment and intangible assets and after repayment of lease liabilities), came to a negative €2.2 million. Operating free cash flow was a positive €5.8 million, excluding non-recurring items related to WCR (discontinuation of factoring and delays in receivables).

Over the half-year, the Group collected €12.7 million net in connection with the management of its business portfolio, including the proceeds from the sale of Distrimed in December 2023 and outflows linked to the acquisitions of Oxigo and Occit'Perf, and earn-outs paid in previous years' acquisitions and minority interest buyouts.

Excluding lease liabilities of €74.6 million, net debt amounted to €324.4 million at December 31, 2023 and shareholders' equity to €83.4 million. Cash and cash equivalents stood at €35.1 million. The Group's leverage (net debt3/annual restated EBITDA4 – excluding IFRS 16 impact), came to 3.41×, a decrease on the calculated leverage at June 30, 2023.

2023-2024 outlook

In light of the trends observed in its markets, Groupe Bastide is confident in continuing its growth trajectory. The Group confirms its annual revenue target of around €530 million like-for-like and a recurring operating margin at least equal to that achieved for fiscal year 2022-2023, i.e., 8.4%.

Debt reduction is the priority for the 2023-2024 fiscal year. In line with the expected improvement in operating free cash flow in the second half of the year, Groupe Bastide intends to accelerate debt reduction, and is continuing to look into the possibility of selling assets that no longer align with its strategy or hinder value creation.


Publication of third-quarter 2023-2024 revenue on

May 15, 2024 after the close of trading


About Groupe Bastide Le Confort Médical

Created in 1977 by Guy Bastide, Groupe Bastide is a leading European provider of home healthcare services. Present in 8 countries, Bastide develops a permanent quality approach and is committed to providing medical devices and associated services that best meet patients' needs in key health areas: diabetes, nutrition, infusion, respiratory care, stomatherapy and urology. Bastide is listed on Euronext Paris (ISIN: FR0000035370, Reuters BATD.PA, - Bloomberg BLC: FP).

Groupe Bastide Actus Finance  
Vincent Bastide/Olivier Jourdanney
T. +33 (0)4 66 38 68 08
Hélène de Watteville
T. +33 (0)1 53 67 36 33 
Press – Media
Anne-Charlotte Dudicourt
T. +33 (0)6 24 03 26 52

Alternative performance indicators (reconciliation)

EBITDA (€ millions) H1 2022-2023 H1 2023-2024
Recurring operating profit 21.5 21.9
 - Net depreciation, amortization and provisions 28.4 31.7
 = EBITDA 49.9 53.6
Operating free cash flow (€ millions) H1 2022-2023 H1 2023-2024
Cash flows from operating activities 52.0 34.3[2]
 - Cash flows from/(used in) financing activities -25.3 -25.7
 - Lease liabilities repaid (IFRS 16) -9.1 -10.8
 = Operating free cash flow 17.6 -2.2

[1] Organic growth calculated at constant exchange rates and on a like-for-like basis, with 2023-2024 figures restated for the contribution of companies acquired within the last 12 months and 2022-2023 figures restated for the contribution of assets sold within the last 12 months.

[2] Of which a negative €8 million in non-recurring items (discontinuation of factoring and late payment of receivables).

This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: ynBvY5abk2mVl5puk8ZuamKWZ5mXmGmYmGqbyJKaZcvInZ+TxplnbZuVZnFlm2xv
- Check this key:

  Original Source: BASTIDE